Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03217032 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lentiviral FVIII Gene Therapy

Name: Lentiviral FVIII Gene Therapy — clinical trial record (NCT03217032)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorShenzhen Geno-Immune Medical Institute

Started2027-06-01

View on ClinicalTrials.gov ↗

This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor VIII into patients with hemophilia A, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.

Amendment history 3 changes detected by DataLookout

2026-09-02

Trial status changed: Recruiting → Not Yet Recruiting

2026-09-02

Primary completion pushed: 2027-05-31 → 2028-05-31

2026-09-02

Completion pushed: 2028-06-01 → 2028-12-01

Trial Details

NCT Number	NCT03217032
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	Hemophilia A
Enrollment	10 participants
Start Date	2027-06-01
Primary Completion	2028-05-31 (estimated)
Study Completion	2028-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-01